Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive ...

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...

San Francisco-based Dolby Labs has reported that its Q1 revenues were at $357 million (€343.8m), a significant increase from ...

H.C. Wainwright & Co. is acting as the exclusive financial advisor to SeaStar Medical in connection with the offering.